SciSparc (SciSparc) FCF Margin % : -292.61% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is SciSparc FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. SciSparc's Free Cash Flow for the six months ended in Dec. 2023 was $-2.65 Mil. SciSparc's Revenue for the six months ended in Dec. 2023 was $0.91 Mil. Therefore, SciSparc's FCF Margin % for the quarter that ended in Dec. 2023 was -292.61%.

As of today, SciSparc's current FCF Yield % is -155.78%.

The historical rank and industry rank for SciSparc's FCF Margin % or its related term are showing as below:

SPRCY' s FCF Margin % Range Over the Past 10 Years
Min: -949.22 Med: -576.85 Max: -204.48
Current: -270.02

During the past 12 years, the highest FCF Margin % of SciSparc was -204.48%. The lowest was -949.22%. And the median was -576.85%.

SPRCY's FCF Margin % is ranked worse than
54.59% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs SPRCY: -270.02

SciSparc FCF Margin % Historical Data

The historical data trend for SciSparc's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciSparc FCF Margin % Chart

SciSparc Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-949.22

-204.48

SciSparc Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-425.32	-163.95	-292.61

Competitive Comparison of SciSparc's FCF Margin %

For the Biotechnology subindustry, SciSparc's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SciSparc's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SciSparc's FCF Margin % distribution charts can be found below:

* The bar in red indicates where SciSparc's FCF Margin % falls into.

SciSparc FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

SciSparc's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-5.887	/	2.879
	=	-204.48 %

SciSparc's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.654	/	0.907
	=	-292.61 %

SciSparc FCF Margin % Related Terms

Thank you for viewing the detailed overview of SciSparc's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SciSparc (SciSparc) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SciSparc Ltd (OTCPK:SPRCY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

SPRC:USA

Address

20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, ISR, 6971916

Website

https://www.scisparc.com

SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority.